ɐ tˈuː θˈaʊzənd nˈaɪn stˈʌdi ʌvðə wˈʌnhˈʌndɹɪd fˈoːɹwˈiːk lˈaɪvz tɹˈaɪəl fˈaʊnd pˈɪɾɐvˌæstɐtˌɪn ɪŋkɹˈiːst ˌeɪtʃdˌiːˈɛl kəlˈɛstɚɹˌɑːl, ɪspˈɛʃəli ɪn pˈeɪʃənts wɪð ˌeɪtʃdˌiːˈɛl lˈoʊɚ ðɐn fˈoːɹɾi ˌɛmdʒˈiː slˈæʃ dˈiː ˈɛl, hˌuː hæd ɐ twˈɛnti fˈoːɹ.sˈɪks pɚsˈɛnt ɹˈaɪz, ɪn ɐdˈɪʃən tə ɡɹˈeɪtli ɹᵻdˈuːsɪŋ ˌɛldˌiːˈɛl kəlˈɛstɚɹˌɑːl θˈɜːɾi wˈʌn.θɹˈiː pɚsˈɛnt.
A 2009 study of the 104-week LIVES trial found pitavastatin increased HDL cholesterol, especially in patients with HDL lower than 40 mg/dL, who had a 24.6% rise, in addition to greatly reducing LDL cholesterol 31.3%.